The incidence of melanoma continues to increase exponentially. It was estimated that, in 2016, 76,380 people in the United States would be diagnosed with melanoma and about 10,130 would die of this disease. Survival rates have started to improve because of new and emerging systemic therapies, including immunotherapy and targeted therapy. The National Comprehensive Cancer Network has updated its guidelines on the use of immunotherapy and targeted therapy in melanoma. Pharmacists can help the clinician select the most appropriate therapy and can actively conduct patient education.